BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian germ cell tumor AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Diagnosis
20 results:

  • 1. The tumor Suppressor brca1/2, Cancer Susceptibility and Genome Instability in Gynecological and Mammary Cancers.
    Oubaddou Y; Ben Ali F; Oubaqui FE; Qmichou Z; Bakri Y; Ameziane El Hassani R
    Asian Pac J Cancer Prev; 2023 Sep; 24(9):3139-3153. PubMed ID: 37774066
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Predicting the Likelihood of Carrying a
    Ang BH; Ho WK; Wijaya E; Kwan PY; Ng PS; Yoon SY; Hasan SN; Lim JMC; Hassan T; Tai MC; Allen J; Lee A; Taib NAM; Yip CH; Hartman M; Lim SH; Tan EY; Tan BKT; Tan SM; Tan VKM; Ho PJ; Khng AJ; Dunning AM; Li J; Easton DF; Antoniou AC; Teo SH
    J Clin Oncol; 2022 May; 40(14):1542-1551. PubMed ID: 35143328
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. An immune-centric exploration of brca1 and BRCA2 germline mutation related breast and ovarian cancers.
    Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
    BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    Valiakhmetova A; Gorelyshev S; Konovalov A; Trunin Y; Savateev A; Kram DE; Severson E; Hemmerich A; Edgerly C; Duncan D; Britt N; Huang RSP; Elvin J; Miller V; Ross JS; Gay L; McCorkle J; Rankin A; Erlich RL; Chudnovsky Y; Ramkissoon SH
    Oncologist; 2020 Feb; 25(2):e198-e202. PubMed ID: 32043779
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. germline and Somatic tumor Testing in Epithelial ovarian Cancer: ASCO Guideline.
    Konstantinopoulos PA; Norquist B; Lacchetti C; Armstrong D; Grisham RN; Goodfellow PJ; Kohn EC; Levine DA; Liu JF; Lu KH; Sparacio D; Annunziata CM
    J Clin Oncol; 2020 Apr; 38(11):1222-1245. PubMed ID: 31986064
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A population-based analysis of germline brca1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
    Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
    BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. White Blood cell brca1 Promoter Methylation Status and ovarian Cancer Risk.
    Lønning PE; Berge EO; Bjørnslett M; Minsaas L; Chrisanthar R; Høberg-Vetti H; Dulary C; Busato F; Bjørneklett S; Eriksen C; Kopperud R; Axcrona U; Davidson B; Bjørge L; Evans G; Howell A; Salvesen HB; Janszky I; Hveem K; Romundstad PR; Vatten LJ; Tost J; Dørum A; Knappskog S
    Ann Intern Med; 2018 Mar; 168(5):326-334. PubMed ID: 29335712
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Metabolomics reveals novel blood plasma biomarkers associated to the brca1-mutated phenotype of human breast cancer.
    Roig B; Rodríguez-Balada M; Samino S; Lam EW; Guaita-Esteruelas S; Gomes AR; Correig X; Borràs J; Yanes O; Gumà J
    Sci Rep; 2017 Dec; 7(1):17831. PubMed ID: 29259228
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
    Enyedi MZ; Jaksa G; Pintér L; Sükösd F; Gyuris Z; Hajdu A; Határvölgyi E; Priskin K; Haracska L
    Oncotarget; 2016 Sep; 7(38):61845-61859. PubMed ID: 27533253
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation.
    Gorodnova TV; Sokolenko AP; Ivantsov AO; Iyevleva AG; Suspitsin EN; Aleksakhina SN; Yanus GA; Togo AV; Maximov SY; Imyanitov EN
    Cancer Lett; 2015 Dec; 369(2):363-7. PubMed ID: 26342406
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Plasma Proteomic Profiling in Hereditary Breast Cancer Reveals a brca1-Specific Signature: Diagnostic and Functional Implications.
    Scumaci D; Tammè L; Fiumara CV; Pappaianni G; Concolino A; Leone E; Faniello MC; Quaresima B; Ricevuto E; Costanzo FS; Cuda G
    PLoS One; 2015; 10(6):e0129762. PubMed ID: 26061043
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less.
    Bayraktar S; Amendola L; Gutierrez-Barrera AM; Hashmi SS; Amos C; Gambello M; Ready KJ; Arun B
    Breast; 2014 Dec; 23(6):770-4. PubMed ID: 25231195
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Pathology of breast and ovarian cancers among brca1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of brca1/2 (CIMBA).
    Mavaddat N; Barrowdale D; Andrulis IL; Domchek SM; Eccles D; Nevanlinna H; Ramus SJ; Spurdle A; Robson M; Sherman M; Mulligan AM; Couch FJ; Engel C; McGuffog L; Healey S; Sinilnikova OM; Southey MC; Terry MB; Goldgar D; O'Malley F; John EM; Janavicius R; Tihomirova L; Hansen TV; Nielsen FC; Osorio A; Stavropoulou A; Benítez J; Manoukian S; Peissel B; Barile M; Volorio S; Pasini B; Dolcetti R; Putignano AL; Ottini L; Radice P; Hamann U; Rashid MU; Hogervorst FB; Kriege M; van der Luijt RB; ; Peock S; Frost D; Evans DG; Brewer C; Walker L; Rogers MT; Side LE; Houghton C; ; Weaver J; Godwin AK; Schmutzler RK; Wappenschmidt B; Meindl A; Kast K; Arnold N; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Varon-Mateeva R; Schönbuchner I; Gevensleben H; Stoppa-Lyonnet D; Belotti M; Barjhoux L; ; Isaacs C; Peshkin BN; Caldes T; de la Hoya M; Cañadas C; Heikkinen T; Heikkilä P; Aittomäki K; Blanco I; Lazaro C; Brunet J; Agnarsson BA; Arason A; Barkardottir RB; Dumont M; Simard J; Montagna M; Agata S; D'Andrea E; Yan M; Fox S; ; Rebbeck TR; Rubinstein W; Tung N; Garber JE; Wang X; Fredericksen Z; Pankratz VS; Lindor NM; Szabo C; Offit K; Sakr R; Gaudet MM; Singer CF; Tea MK; Rappaport C; Mai PL; Greene MH; Sokolenko A; Imyanitov E; Toland AE; Senter L; Sweet K; Thomassen M; Gerdes AM; Kruse T; Caligo M; Aretini P; Rantala J; von Wachenfeld A; Henriksson K; ; Steele L; Neuhausen SL; Nussbaum R; Beattie M; Odunsi K; Sucheston L; Gayther SA; Nathanson K; Gross J; Walsh C; Karlan B; Chenevix-Trench G; Easton DF; Antoniou AC;
    Cancer Epidemiol Biomarkers Prev; 2012 Jan; 21(1):134-47. PubMed ID: 22144499
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and brca1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
    Buecher B; Gauthier-Villars M; Desjardins L; Lumbroso-Le Rouic L; Levy C; De Pauw A; Bombled J; Tirapo C; Houdayer C; Bressac-de Paillerets B; Stoppa-Lyonnet D
    Fam Cancer; 2010 Dec; 9(4):663-7. PubMed ID: 20842456
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Functional variant of KLOTHO: a breast cancer risk modifier among brca1 mutation carriers of Ashkenazi origin.
    Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
    Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Potential excess mortality in brca1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma.
    Mai PL; Chatterjee N; Hartge P; Tucker M; Brody L; Struewing JP; Wacholder S
    PLoS One; 2009; 4(3):e4812. PubMed ID: 19277124
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Preimplantation genetic diagnosis for cancer predisposition syndromes.
    Spits C; De Rycke M; Van Ranst N; Verpoest W; Lissens W; Van Steirteghem A; Liebaers I; Sermon K
    Prenat Diagn; 2007 May; 27(5):447-56. PubMed ID: 17330926
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Pancreatic adenocarcinoma: epidemiology and genetics.
    Flanders TY; Foulkes WD
    J Med Genet; 1996 Nov; 33(11):889-98. PubMed ID: 8950667
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.